Microscopic clues may forecast bladder Cancer's next move
NCT ID NCT07529639
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study examines two microscopic details in bladder cancer tumors—how deep early cancer cells have invaded and whether small clusters of cells are present at the tumor's edge. Researchers will look at tissue samples from 100 patients to see if these features can predict if the cancer will come back or spread. The goal is to better understand which patients need more aggressive treatment, but no new therapy is being tested.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
May 2026
An estimate. Start dates often move.
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population consists of patients diagnosed with urothelial bladder carcinoma who underwent transurethral resection (TUR) at the South Egypt Cancer Institute (SECI), Assiut University, between the years 2018 and 2024. The study utilizes retrospectively collected, archived paraffin-embedded tissue blocks along with corresponding clinical, pathological, and survival data retrieved from medical records and electronic pathology reports.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with a urinary bladder mass, diagnosed by TUR biopsy as urothelial carcinoma. * Patients with full clinical data and complete medical reports. Exclusion Criteria: * Cases with non-urothelial histological subtypes (e.g., pure squamous cell carcinoma). * Patients who received neoadjuvant chemotherapy or radiotherapy. * Cases with missing or inaccessible clinical follow-up data. * History of prior or concurrent malignancy.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bladder carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can heated saline during bladder surgery stop tumors from coming back?
- Blood test aims to catch Cancer's return earlier
- Can a bladder rinse before surgery keep bladder cancer at bay?
- Can a home care plan ease bladder cancer treatment side effects?
- Can tumor avatars reveal why cancer hits minorities harder?
- Can a new drug help keep bladder cancer at bay?